Tumour infiltrating lymphocytes
Latest Information Update: 15 Jan 2008
At a glance
- Originator National Institutes of Health (USA)
- Class Antineoplastics; Cell therapies; Immunotherapies
- Mechanism of Action Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer; Non-small cell lung cancer; Renal cancer